CoronaVirus Watch List Stocks in the News (Bloomberg, Benzinga).

INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40   Alpha Pro Tech, Ltd. (NYSE: APT) $6.00AstraZeneca plc (NYSE: AZN) $49BioCryst Pharmaceuticals, Inc.'s (NASDAQ: BCRX) $2.80  Cerus Corporation (NASDAQ: CERS)...
Citius Pharmaceutical, CTXR, Biotech Stock Review

New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.

Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the Biotech Stock...

Citius Pharma (CTXR) Corporate Presentation (Jan 2020).

In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic below) at...

Candida Auris: Hospitals mobilize to fight the deadly infection (Video). More Videos Below.

https://youtu.be/hnqFdKSG6-A Auris all over the room, even on the ceiling?. https://youtu.be/ypyNoM5z40s Are hospitals keeping real-time infection status a secret? https://www.youtube.com/watch?v=IOX3JdLvm1Y ARTICLES: A Mysterious Infection, Spanning the Globe in a Climate...
steven boyd, biotech stock review

Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).

April 2019 Offering On April 1, 2019, Citius entered into securities purchase agreements with institutional investors and accredited investors for the sale by us of...
AR THreats Report, Biotech Stock Reciew

AR Threats Report (CDC)

This report is dedicated to the 48,700 familieswho lose a loved one each year to antibiotic resistanceor Clostridioides difficile, and the countless healthcareproviders, public...
candida auris, citius pharma, biotech stock review

Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.

CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided...

Latest article

Jeffrey Gundlach: Reckoning is Coming.

Jeffrey Edward Gundlach is a businessman, fund manager, and philanthropist. He is the founder of DoubleLine Capital, an investment firm. On 11 November 2020, Gundlach remarked in an interview with...

Who’s the Next Eric Sprott?

To say Eric Sprott has left a legendary mark on the world of mining investment would be an understatement. With a career spanning five...

Perpetua (PPTA) Raises $300 Million.

Not a bad day in Idaho. $300 million banked! We look at the dip as a buying opportunity, as does John Paulson & Co.,...